{
  "id": 21222681,
  "title": "Johnson & Johnson Is on Track for $101 Billion in 2026 Sales. Is This Dividend King Still a Buy?",
  "url": "https://urgent.news/2026/11/22/johnson-johnson-is-on-track-for-101-billion-in-2026-sales-is-this",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-22T13:38:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/11/22/johnson-johnson-is-on-track-for-101-billion-in-2026-sales-is-this-dividend-king-still-a-buy/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Johnson & Johnson (JNJ) continues its impressive streak of long-term performance and dividend growth. Founded over a century ago, the healthcare giant has increased its dividend for an astonishing 64 consecutive years, earning its status as a Dividend King and the longest streak among healthcare companies. Recently, J&J released its full-year guidance for 2026, projecting revenue of $101.2 billion and earnings per share of $11.10, representing modest improvements over previous estimates. Despite this solid guidance, the stock's yield of 1.9% remains below the market average and lower than other healthcare stocks, which has deterred investors seeking maximum income. Additionally, J&J's valuation appears to be expensive, with a price-to-sales ratio of 6.8x, a price-to-earnings ratio of 42x, and a price-to-book ratio of 8.2x, all of which exceed their five-year averages. While this high valuation may discourage value investors, Johnson & Johnson remains a strong option for conservative, income-oriented investors who appreciate consistent dividends. The stock could be considered a wish-list stock for those willing to pay a premium for quality, particularly during market downturns when valuation opportunities may arise. However, investors seeking a diversified healthcare stock with a premium price tag and above-average yield may find that J&J does not fit their current portfolio needs. Nonetheless, for those with a long-term perspective and a value focus, J&J's reliable dividend and consistent performance make it a compelling choice.",
  "summary": "J&J is a healthcare giant performing very well right now, but it won't be a great fit for every investor.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Johnson & Johnson Is on Track for $101 Billion in 2026 Sales. Is This Dividend King Still a Buy?",
        "url": "https://urgent.news/2026/11/22/johnson-johnson-is-on-track-for-101-billion-in-2026-sales-is-this-21224160",
        "published": "2026-11-22T13:58:02.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}